MeSH tree: D12.776.631.650.300
Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published ...
Mar 10, 2026
0
73
Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be effective at treating and preventing substance-use disorders across all major addictive substances ...
Mar 4, 2026
0
43
Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years. Despite its clinical success, its precise molecular and cellular mechanisms are still ...
Feb 24, 2026
0
15
Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened some 8,000 or more Marylanders a year by 2024. The Food and Drug Administration has announced that ...
Feb 24, 2026
0
18
For the first time, researchers show that tirzepatide—the active ingredient in the diabetes and weight-loss drug Mounjaro—reduces alcohol intake as well as relapse-like behaviors in rats and mice. The findings are considered ...
Feb 20, 2026
0
16
The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. ...
Feb 11, 2026
0
8
GLP-1 drugs have ushered in a new era in weight loss.
Feb 7, 2026
0
26
In the world of obesity research, the arrival of GLP-1 drugs like Ozempic feels seismic. At a recent conference, Martin Binks, a leader in obesity research, found himself marveling with a colleague: "Can you believe we finally ...
Feb 3, 2026
0
13
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight ...
Jan 23, 2026
0
17
With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes.
Jan 22, 2026
0
16
